ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on X

Kidney Week

Please note that you are viewing an archived section from 2022 and some content may be unavailable. To unlock all content for 2022, please visit the archives.

Abstract: SA-PO268

Consistent Kidney Benefits With Semaglutide vs. Placebo Regardless of Baseline Urine Albumin Creatinine Ratio in Subjects With Type 2 Diabetes at High Cardiovascular Risk: A Post Hoc Analysis of SUSTAIN 6

Session Information

Category: Diabetic Kidney Disease

  • 602 Diabetic Kidney Disease: Clinical


  • L Heerspink, Hiddo Jan, University Medical Center Groningen, Groningen, Netherlands
  • Kuhlman, Anja Birk, Novo Nordisk A/S, Søborg, Denmark
  • Mann, Johannes F., KfH Kidney Center, München, Germany
  • Rasmussen, Soren, Novo Nordisk A/S, Søborg, Denmark
  • Rossing, Peter, Steno Diabetes Center Copenhagen, Herlev, Denmark
  • Vrhnjak, Blaz, Novo Nordisk A/S, Søborg, Denmark
  • Cherney, David, University Health Network, Toronto, Ontario, Canada

In a previous analysis of SUSTAIN 6 and PIONEER 6 (cardiovascular [CV] outcomes trials in subjects with type 2 diabetes [T2D] at high CV risk), semaglutide reduced estimated glomerular filtration rate (eGFR) slope vs placebo, both in addition to standard of care antidiabetes medication. This was most pronounced in those with eGFR <60 mL/min/1.73 m2; it is of clinical interest to understand if this benefit is consistent across urine albumin:creatinine ratio (UACR) groups. The aim of this post hoc analysis was to investigate the effects of semaglutide on eGFR slopes in subjects with different albuminuria levels at baseline in SUSTAIN 6 (PIONEER 6 was excluded as UACR was not collected in this trial).


eGFR slope estimated by a random effect model was compared in subjects by baseline UACR: <30/≥30−≤300/>300 mg/g. To account for potential differences in baseline characteristics, a sensitivity analysis was performed. These subgroups were also compared in those with baseline eGFR ≥30−<60 or ≥60 mL/min/1.73 m2.


Across the three subgroups (N=3,232), baseline characteristics were similar, except for higher blood pressure and lower eGFR in subjects with UACR >300 mg/g vs other subgroups. Overall, subjects receiving semaglutide had a slower decline in eGFR at 2 years vs placebo, an effect that was consistent across the three subgroups (p-value for interaction: 0.99; Figure). Results were consistent in the sensitivity analysis and those with eGFR ≥30−<60 vs ≥60 mL/min/1.73 m2.


Semaglutide appears to slow eGFR decline vs placebo in subjects with T2D at high CV risk regardless of baseline albuminuria status.

Estimated annual eGFR slopes according to treatment and UACR groups at baseline


  • Commercial Support –